Ovarian cancer risk associated with inherited inflammation- related variants

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1064-1069

  White, Kristin L ^a,b   Schildkraut, Joellen M ^c   Palmieri, Rachel T ^d   Iversen, Edwin S ^e   Berchuck, Andrew ^c   Vierkant, Robert A ^a   Rider, David N ^a   Charbonneau, Bridget ^a   Cicek, Mine S ^a   Sutphen, Rebecca ^f   Birrer, Michael J ^g   Pharoah, Paul P D ^h   Song, Honglin ^h   Tyrer, Jonathan ^h   Gayther, Simon A ⁱ   Ramus, Susan J ⁱ   Wentzensen, Nicolas ^j   Yang, Hannah P ^j   Garcia Closas, Montserrat ^k   Phelan, Catherine M ^l   Cunningham, Julie M ^a   Fridley, Brooke L ^a   Sellers, Thomas A ^l   Goode, Ellen L ^a   more..

^a Mayo Clinic   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d IL   (United States)

^e Duke University   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE GENE; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; INTERLEUKIN 1ALPHA GENE; MAJOR CLINICAL STUDY; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863288741     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3512     Document Type: Article

References (20)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse- Jones K, et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 2007;28:1207-15. (Pubitemid 350250385)
3. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42:880-4.
4. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifiessusceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42:874-9.
5. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res 2010;8:1453-65.
6. Cramer DW, Finn OJ. Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 2011;23:265-71.
7. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
8. Rocconi RP, Kirby TO, Seitz RS, Beck R, Straughn JM Jr, Alvarez RD, et al. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008;15:321-6. (Pubitemid 351550943)
9. Lurie G, Terry K, Wilkens L, Thompson P, McDuffie K, Carney M, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010;21:1731-41.
10. White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, et al. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer 2009;9:170.
11. Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res 2011;71:3896-903.
12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
13. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011;70 Suppl 1:i104-8.
14. Shen J, Deininger PL, Zhao H. Applications of computational algorithm tools to identify functional SNPs in cytokine genes. Cytokine 2006;35:62-6. (Pubitemid 44485537)
15. Sims AM, Timms AE, Bruges-Armas J, Burgos-Vargas R, Chou CT, Doan T, et al. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis 2008;67:1305-9.
16. Sigurdson AJ, Bhatti P, Doody MM, Hauptmann M, Bowen L, Simon SL, et al. Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists. Cancer Epidemiol Biomarkers Prev 2007; 16:2000-7. (Pubitemid 47621173)
17. Han W, Kang SY, Kang D, Park SK, Lee JY, Kim H, et al. Multiplex genotyping of 1107 SNPs from 232 candidate genes identified an association between IL1A polymorphism and breast cancer risk. Oncol Rep 2010;23:763-9.
18. Hefler LA, Ludwig E, Lebrecht A, Zeillinger R, Tong-Cacsire D, Koelbl H, et al. Polymorphisms of the interleukin-1 gene cluster and ovarian cancer. J Soc Gynecol Investig 2002;9:386-90. (Pubitemid 35351343)
19. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res 2010;16:995-1007.
20. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42. (Pubitemid 38443646)